ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
43 announcements with these filters
Rossari Biotech Limited announced that Ms. Aparna Sharma (DIN: 07132341) completed her tenure as an Independent Director on April 28, 2026. Consequently, she ceased to be a director and committee member from the end of that day. The board expressed appreciation for her contributions during her association with the company.
Rossari Biotech reported highest-ever quarterly revenue of ₹684.9 cr and EBITDA of ₹77.3 cr in Q4 FY26. Performance driven by HPPC segment (77% of revenue) and capacity expansions.
Rossari Biotech announced its FY26 results, reporting 15% revenue growth to ₹2,396.40 Crore. Q4 FY26 revenue reached a record ₹684.9 Crore, up 18% YoY, while annual PAT rose 9% to ₹149.2 Crore. The company also commissioned 15,000 MTPA additional capacity at its Dahej facility and recommended a ₹0.50 per share dividend.
Rossari Biotech Limited's board recommended a final dividend of 25% (₹0.50 per equity share) for the financial year 2025-26. The record date and general meeting date will be announced later. This proposal is subject to shareholder approval.
Rossari Biotech Limited has appointed Mr. Udeypaul Singh Gill as a Non-Executive Independent Director for a 36-month term effective April 28, 2026. Mr. Gill brings over forty years of experience in chemicals, textiles, and sustainability. The appointment follows a board meeting outcome to strengthen the company's strategic leadership.
Rossari Biotech Limited allotted 8,250 equity shares on April 27, 2026, under its Employee Stock Option Plan - 2019. This allotment increased the company's paid-up share capital from ₹11.08 Crore to ₹11.08 Crore (specifically 5,53,91,616 shares).
Rossari Biotech Ltd reported revenue from operations of ₹684.9 Cr (+18.2% YoY) and net profit of ₹46 Cr (+33.7% YoY) for Q4 FY26.
Rossari Biotech reported consolidated total income of ₹2,418.74 Crore for FY26. The Board recommended a final dividend of ₹0.50 per share (25%) and appointed Mr. Udeypaul Singh Gill as an Independent Director. Additionally, the company approved a new R&D facility in Navi Mumbai and an update on its capacity expansion project.
Rossari Biotech Limited announced a rescheduling of its capacity expansion project at subsidiaries Unitop Chemicals and Tristar Intermediates. The investment plan is being re-evaluated due to evolving market conditions and will now be implemented in phases over the next two years. The company's overall strategic intent for the expansion remains unchanged.
Rossari Biotech Limited has scheduled a Board Meeting for April 27, 2026, to approve the audited standalone and consolidated financial results for the year ended March 31, 2026. The Board will also consider recommending a final dividend. The trading window remains closed until April 29, 2026.
Rossari Biotech Limited has scheduled a Board Meeting on April 27, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend. Consequently, the trading window for designated persons remains closed from April 01, 2026.
Rossari Biotech's subsidiary, Unitop Chemicals, approved the sale of its Mumbai office premises for approximately ₹10 Crore. The transaction is expected to conclude by Q2 FY27. As no business operations are conducted there, the sale will not impact the company's core operations.
Rossari Biotech Limited submitted its compliance certificate for the quarter ended March 31, 2026, as required under SEBI regulations. The registrar, MUFG Intime India, confirmed the processing of share dematerialisation requests within prescribed timelines. This is a routine regulatory filing with no material financial impact.